{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:59:50Z","timestamp":1773665990814,"version":"3.50.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,4,1]]},"DOI":"10.1093\/jjco\/hym017","type":"journal-article","created":{"date-parts":[[2007,5,23]],"date-time":"2007-05-23T17:36:19Z","timestamp":1179941779000},"page":"302-309","source":"Crossref","is-referenced-by-count":22,"title":["Clinical Experience with Transdermal and Orally Administered Opioids in Palliative Care Patients\u2014A Retrospective Study"],"prefix":"10.1093","volume":"37","author":[{"given":"Katri Elina","family":"Clemens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eberhard","family":"Klaschik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2007,5,22]]},"reference":[{"key":"key\n\t\t\t\t20171012005333_HYM017C1","first-page":"1","article-title":"Symptom management in cancer: pain, depression, and fatigue","author":"Zorn","year":"2002"},{"key":"key\n\t\t\t\t20171012005333_HYM017C2","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1056\/NEJM199403033300902","article-title":"Pain and its treatment in outpatients with metastatic cancer","volume":"330","author":"Cleeland","year":"1994","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171012005333_HYM017C3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1056\/NEJM198507113130205","article-title":"The treatment of cancer pain","volume":"313","author":"Foley","year":"1985","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171012005333_HYM017C4","article-title":"Cancer Pain Relief","author":"Report of a WHO Expert Committee","year":"1996"},{"key":"key\n\t\t\t\t20171012005333_HYM017C5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1054\/bjoc.2001.1680","article-title":"Morphine and alternative opioids in cancer pain: the EAPC recommendations","volume":"84","author":"Hanks","year":"2001","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20171012005333_HYM017C6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s004820050142","article-title":"Hydromorphon\u2014pharmakologische Eigenschaften und therapeutische Wirksamkeit","volume":"12","author":"Lindena","year":"1998","journal-title":"Schmerz"},{"key":"key\n\t\t\t\t20171012005333_HYM017C7","first-page":"24","article-title":"Cancer Pain and Palliative Care","volume":"804","author":"Report of the WHO Expert Committee","year":"1990","journal-title":"World Health Organ Techn Rep Ser"},{"key":"key\n\t\t\t\t20171012005333_HYM017C8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0885-3924(95)90012-8","article-title":"Hydromorphone and metabolite pharmacokinetics in children","volume":"10","author":"Babul","year":"1995","journal-title":"J Pain Symptom Manage"},{"key":"key\n\t\t\t\t20171012005333_HYM017C9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1984.2.3.187","article-title":"Karnofsky performance status revisited: reliability, validity, and quidelines","volume":"2","author":"Schag","year":"1984","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20171012005333_HYM017C10","article-title":"Cancer Pain Relief","author":"World Health Organization","year":"1986"},{"key":"key\n\t\t\t\t20171012005333_HYM017C11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0885-3924(97)00082-1","article-title":"Transdermal fentanyl versus sustained release oral morphine in cancer pain: preference, efficacy and quality of life","volume":"13","author":"Ahmedzai","year":"1997","journal-title":"J Pain Symptom Manage"},{"key":"key\n\t\t\t\t20171012005333_HYM017C12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1470-2045(00)00258-8","article-title":"Treatment of cancer pain with transdermal fentanyl","volume":"2","author":"Gourlay","year":"2001","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20171012005333_HYM017C13","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.1998.16.4.1588","article-title":"Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine","volume":"16","author":"Payne","year":"1998","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20171012005333_HYM017C14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00003495-199753010-00011","article-title":"Transdermal fentanyl. A review of its efficacy in pain control","volume":"53","author":"Jeal","year":"1997","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20171012005333_HYM017C15","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1200\/JCO.1998.16.10.3213","article-title":"Methadone in cancer pain management: individualize dose and titrate to effect","volume":"16","author":"Foley","year":"1998","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20171012005333_HYM017C16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/026921639701100308","article-title":"Transdermal fentanyl for severe cancer-related pain","volume":"11","author":"Yeo","year":"1997","journal-title":"Palliat Med"},{"key":"key\n\t\t\t\t20171012005333_HYM017C17","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1002\/cncr.20712","article-title":"Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain","volume":"101","author":"Benitez-Rosario","year":"2004","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20171012005333_HYM017C18","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2165\/00003495-200161150-00014","article-title":"Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain","volume":"61","author":"Muijsers","year":"2001","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20171012005333_HYM017C19","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1001\/jama.293.24.3043","article-title":"Efficacy of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trias","volume":"293","author":"Eisenberg","year":"2005","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171012005333_HYM017C20","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.2174\/1381612054865055","article-title":"Opioids in neuropathic pain","volume":"11","author":"Przewlocki","year":"2005","journal-title":"Curr Pharm Des"},{"key":"key\n\t\t\t\t20171012005333_HYM017C21","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/cncr.10518","article-title":"A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral oipioids","volume":"94","author":"Enting","year":"2002","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20171012005333_HYM017C22","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1002\/1097-0142(20011001)92:7<1919::AID-CNCR1710>3.0.CO;2-G","article-title":"Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl","volume":"92","author":"Santiago-Palma","year":"2001","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20171012005333_HYM017C23","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/0885-3924(95)90924-C","article-title":"Opioid rotation for toxicity reduction in terminal cancer patients","volume":"10","author":"DeStoutz","year":"1995","journal-title":"J Pain Symptom Manage"},{"key":"key\n\t\t\t\t20171012005333_HYM017C24","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/archinte.160.6.786","article-title":"Occurrence, causes and outcome of delirium in patients with advanced cancer: a prospective study","volume":"160","author":"Lawlor","year":"2000","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20171012005333_HYM017C25","first-page":"28","article-title":"Opioid use and health care charges at the end of life in patients with metastatic cancer","volume":"17","author":"Berger","year":"2004","journal-title":"Manag Care Interface"},{"key":"key\n\t\t\t\t20171012005333_HYM017C26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1191\/0269216305pm971oa","article-title":"Physicians' knowledge of transdermal fentanyl","volume":"19","author":"Welsh","year":"2005","journal-title":"Palliat Med"},{"key":"key\n\t\t\t\t20171012005333_HYM017C27","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0885-3924(02)00507-9","article-title":"Care of dying: is pain control compromised or enhanced continuation of the fentayl transdermal patch in the dying phase?","volume":"24","author":"Ellershaw","year":"2002","journal-title":"J Pain Symptom Manage"},{"issue":"322,7295","key":"key\n\t\t\t\t20171012005333_HYM017C28","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/bmj.322.7295.1154","article-title":"Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain","volume":"12","author":"Allan","year":"2001","journal-title":"Br Med J"},{"key":"key\n\t\t\t\t20171012005333_HYM017C29","first-page":"8","article-title":"New strategies in opioid therapy for cancer pain","volume":"9","author":"Cherny","year":"2000","journal-title":"J Oncol Manag"},{"key":"key\n\t\t\t\t20171012005333_HYM017C30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2302\/kjm.53.23","article-title":"Clinical experience with transdermal fentanyl for the treatment of cancer pain in Germany","volume":"53","author":"Radbruch","year":"2004","journal-title":"Keio J Med"},{"key":"key\n\t\t\t\t20171012005333_HYM017C31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003088-200038010-00004","article-title":"Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl","volume":"38","author":"Grond","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20171012005333_HYM017C32","article-title":"Durogesic (fentanyl transdermal system) [drug summary information]","author":"Janssen Pharmaceutica Products"},{"key":"key\n\t\t\t\t20171012005333_HYM017C33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0304-3959(97)00018-3","article-title":"Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study","volume":"7","author":"Lawlor","year":"1997","journal-title":"Pain"},{"key":"key\n\t\t\t\t20171012005333_HYM017C34","first-page":"22","article-title":"Hydromorphone. A first-line analgesic without clinically relevant metabolites","volume":"101","author":"Pasero","year":"2001","journal-title":"Am J Nurs"},{"key":"key\n\t\t\t\t20171012005333_HYM017C35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0885-3924(01)00271-8","article-title":"Accuracy in equianalgesic dosing conversion dilemmas","volume":"21","author":"Anderson","year":"2001","journal-title":"J Pain Symptom Manage"},{"key":"key\n\t\t\t\t20171012005333_HYM017C36","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0885-3924(01)00294-9","article-title":"Equianalgesic dose ratios for opioids. A critical review and proposals for long term dosing","volume":"22","author":"Pereira","year":"2001","journal-title":"J Pain Symptom Manage"},{"key":"key\n\t\t\t\t20171012005333_HYM017C37","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1200\/JCO.2005.13.128","article-title":"Rapid switching between transdermal fentanyl and metadone in cancer patients","volume":"23","author":"Mercandante","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"key\n\t\t\t\t20171012005333_HYM017C38","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004847","article-title":"Opioid switching to improve pain relief and drug tolerability","author":"Quigley","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20171012005333_HYM017C39","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0885-3924(95)00005-J","article-title":"Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration and opiate rotation","volume":"10","author":"Bruera","year":"1995","journal-title":"J Pain Symptom Manage"},{"key":"key\n\t\t\t\t20171012005333_HYM017C40","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0304-3959(93)90232-E","article-title":"Opioid hyper excitability\u2014the application of alternate opioid therapy","volume":"53","author":"MacDonald","year":"1993","journal-title":"Pain"},{"key":"key\n\t\t\t\t20171012005333_HYM017C41","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/0304-3959(92)90270-L","article-title":"Putative role of hydromorphone metabolites in myoclonus","volume":"51","author":"Babul","year":"1992","journal-title":"Pain"},{"key":"key\n\t\t\t\t20171012005333_HYM017C42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/j.1552-4604.1995.tb04743.x","article-title":"Steady state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled release hydromorphone","volume":"35","author":"Hagen","year":"1995","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20171012005333_HYM017C43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejpain.2004.05.008","article-title":"Genetics and variability in opioid response","volume":"9","author":"Stamer","year":"2005","journal-title":"Eur J Pain"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/37\/4\/302\/5191646\/hym017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T04:54:11Z","timestamp":1507784051000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jjco\/article\/37\/4\/302\/969354\/Clinical-Experience-with-Transdermal-and-Orally"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,1]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2007,5,22]]},"published-print":{"date-parts":[[2007,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hym017","relation":{},"ISSN":["1465-3621","0368-2811"],"issn-type":[{"value":"1465-3621","type":"electronic"},{"value":"0368-2811","type":"print"}],"subject":[],"published-other":{"date-parts":[[2007,4]]},"published":{"date-parts":[[2007,4,1]]}}}